Skip to Main Content

Paper Details

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Mult Scler Relat Disord
7
2023
1-phosphate, B.1.1.529, BA, CD20, COVID, COVID-19, MS, Omicron, Participants, People, S1PR, SARS, SARS-CoV-2, Spike antigen, T cell, WA1, anti-, anti-CD20, coronavirus disease, multiple sclerosis, participants, people, severe, severe acute respiratory syndrome coronavirus 2, sphingosine, sphingosine receptor-1
Author NameAffiliation
Sacha GnjaticPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai
Sacha GnjaticPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai
Miriam MeradPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai
Miriam MeradPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 4

Datasets

Release 1.2